Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Chelerythrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 5/20 | 0.90 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.90 |
| ▸ | MAPT | P10636 | 7/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.90 |
| ▸ | HPGD | P15428 | 5/20 | 0.90 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.90 |
| ▸ | BCHE | P06276 | 5/20 | 0.90 |
| ▸ | LMNA | P02545 | 5/20 | 0.90 |
| ▸ | RAC1 | P63000 | 4/20 | 0.90 |
| ▸ | GMNN | O75496 | 2/20 | 0.90 |
| ▸ | POLB | P06746 | 2/20 | 0.90 |
| ▸ | BLM | P54132 | 2/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.90 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.90 |
| ▸ | BAD | Q92934 | 2/20 | 0.90 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.88 |
| ▸ | MEN1 | O00255 | 4/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chelerythrine SCHEMBL195109 | 0.95 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL30207103 | 0.95 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL30527167 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL30527168 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL288915 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL29357531 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL4016265 | 0.92 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL4980861 | 0.92 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL3319851 | 0.92 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL288916 | 0.92 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299044-A1 | SYSTEMS AND METHODS FOR DELIVERY OF DRUGS AND OTHER SUBSTANCES COMPRISING DEEP EUTECTIC SOLVENTS | Novilla Pharmaceuticals, Inc. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3829541-A1 | SYSTEMS AND METHODS FOR DELIVERY OF DRUGS AND OTHER SUBSTANCES COMPRISING DEEP EUTECTIC SOLVENTS | Novilla Pharmaceuticals, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-112839634-A | Systems and methods for delivering drugs and other substances including deep eutectic solvents | 诺维拉制药有限公司 | 2021-05-25 | — | — | CN | disclosed |
| WO-2020028471-A1 | SYSTEMS AND METHODS FOR DELIVERY OF DRUGS AND OTHER SUBSTANCES COMPRISING DEEP EUTECTIC SOLVENTS | BULLSEYETX LLC (US) | 2020-02-06 | — | — | WO | disclosed |
| US-9238053-B2 | Methods for treatment of pain | NOCICEPTA LLC (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2459183-B1 | METHODS FOR TREATMENT OF PAIN | NOCICEPTA LLC (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2179741-B1 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATON OF OXYTOCIN | UNIV LELAND STANFORD JUNIOR (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8551949-B2 | Methods for treatment of pain | NOCICEPTA LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-8501691-B2 | Methods for treatment of headaches by administration of oxytocin | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130196908-A1 | METHODS FOR TREATMENT OF PAIN | TRIGEMINA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120028898-A1 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN | HEALTHPARTNERS RESEARCH & EDUCATION | 2012-02-02 | — | — | US | disclosed |
| WO-2011017122-A1 | METHODS FOR TREATMENT OF PAIN | TRIGEMINA INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20110021426-A1 | METHODS FOR TREATMENT OF PAIN | TONIX PHARMA LIMITED (IE) | 2011-01-27 | — | — | US | disclosed |
| EP-2179741-A1 | Methods for treatment of headaches by administraton of oxytocin | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-1928484-B1 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN | UNIV LELAND STANFORD JUNIOR (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090291900-A1 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN | HEALTHPARTNERS RESEARCH & EDUCATION | 2009-11-26 | — | — | US | disclosed |
| US-20090181880-A1 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN | HEALTHPARTNERS RESEARCH & EDUCATION | 2009-07-16 | — | — | US | disclosed |
| EP-1928484-A2 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070054843-A1 | Methods for treatment of headaches by administration of oxytocin | HEALTHPARTNERS RESEARCH FOUNDATION | 2007-03-08 | — | — | US | disclosed |
| WO-2007025249-A2 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299044-A1 | SYSTEMS AND METHODS FOR DELIVERY OF DRUGS AND OTHER SUBSTANCES COMPRISING DEEP EUTECTIC SOLVENTS | PTGES, PTGER3, PTGES3 | ACHE 384/4885CHRM1 3144/4885ALDH1A1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.